FDA delays approval of Alzheimer’s drug donanemab: What experts think
Eli Lilly & Company, the maker of anti-amyloid Alzheimer’s treatments, was expecting its experimental drug donanemab to be approved by the FDA this month. However, the FDA has said it will hold a panel with...
Read More